Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
50 hedge funds and large institutions have $6.23M invested in Oncternal Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 15 closing their positions.
6% more call options, than puts
Call options by funds: $113K | Put options by funds: $107K
9% less funds holding
Funds holding: 55 → 50 (-5)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
38% less capital invested
Capital invested by funds: $10M → $6.23M (-$3.79M)
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$160K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$158K |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$107K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$81.1K |
| 5 |
SFM
Soros Fund Management
New York
|
+$55.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$918K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$574K |
| 3 |
State Street
Boston,
Massachusetts
|
-$495K |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$330K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$168K |
ONCT Hedge Fund Activity: Q2 2014 in Review
50 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2014, worth a combined $6.23M — down 38% from $10M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ONCT and 10 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Bank of America, adding an estimated $160K. The largest seller was BlackRock Fund Advisors, cutting an estimated $918K.
- 50 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2014, down from 55 in Q1 2014.
- Funds reported $6.23M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2014, down 38% quarter-over-quarter.
- 10 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2014 and 15 closed out, a net change of -5 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2014 was Bank of America, an estimated $160K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2014 was BlackRock Fund Advisors, an estimated $918K sold.
Based on aggregated 13F filings for Q2 2014.